Phibro Animal Health Corporation
Price History
Company Overview
Business Model: Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It generates revenue through the development, manufacture, and marketing of approximately 800 product lines, including antibacterials, anticoccidials, nutritional specialty products, vaccines, vaccine adjuvants, and ethanol fermentation processing aids for livestock. The company also manufactures and markets trace minerals and specialty ingredients for personal care, industrial chemical, and chemical catalyst industries.
Market Position: Phibro Animal Health Corporation markets its products in about 90 countries to approximately 4,500 customers. The company's business is concentrated in the livestock sector, serving poultry, swine, beef and dairy cattle, and aquaculture. Following a significant acquisition, Phibro Animal Health Corporation believes its medicated feed additive sales were the third largest in the animal health market. The company is also investing in companion animal products.
Recent Strategic Developments: In April 2024, Phibro Animal Health Corporation entered into an agreement with Zoetis Inc. to acquire its medicated feed additive portfolio, certain water-soluble products, and related assets. This acquisition closed on October 31, 2024, for approximately $297.5 million (net of cash acquired), funded by term loan borrowings. The acquired portfolio generated $407.6 million in revenue in 2023 and contributed $208.2 million to Phibro Animal Health Corporation’s net sales for the fiscal year ended June 30, 2025. The company also expanded its vaccine manufacturing capabilities with a new facility in Guarulhos, Brazil, launched in fiscal year 2023, and plans to expand its Sligo, Ireland vaccine facility to include swine and cattle vaccines. Phibro Animal Health Corporation is developing a companion animal pipeline, including Rejensa® joint care supplement for dogs, a potential treatment for mitral valve disease in dogs, a novel pain management product, and two oral care formulations.
Geographic Footprint: Phibro Animal Health Corporation operates globally, marketing products in approximately 90 countries. Its primary operational regions include the United States, Latin America and Canada, Europe, Middle East and Africa, and Asia Pacific. International operations contributed approximately 55% of Animal Health net sales for fiscal year 2025.
Financial Performance
Revenue Analysis
| Metric | Current Year (2025) | Prior Year (2024) | Change |
|---|---|---|---|
| Total Revenue | $1,296.2 million | $1,017.7 million | +27% |
| Gross Profit | $399.9 million | $313.1 million | +28% |
| Operating Income | $110.5 million | $53.3 million | +$57.2 million |
| Net Income | $48.3 million | $2.4 million | +$45.8 million |
Profitability Metrics:
- Gross Margin: 30.9%
- Operating Margin: 8.5%
- Net Margin: 3.7%
Investment in Growth:
- R&D Expenditure: $23.7 million (1.8% of revenue)
- Capital Expenditures: $38.3 million
- Strategic Investments: The acquisition of Zoetis Inc.'s medicated feed additive portfolio and related assets for approximately $297.5 million (net of cash acquired) in fiscal year 2025.
Business Segment Analysis
Animal Health
Financial Performance:
- Revenue: $963 million (+36.4% YoY)
- Operating Margin: Adjusted EBITDA was $222 million (23.0% of segment revenue)
- Key Growth Drivers: Significant growth driven by the acquisition of Zoetis Inc.'s medicated feed additive portfolio, which contributed $208.2 million to net sales in fiscal year 2025. Growth was also observed across all product groups and species categories.
Product Portfolio:
- MFAs and other: Antibacterials (Stafac®, Terramycin®, Neo-Terramycin®, Mecadox®, Aureomycin®, LincoSpectin®, BMD®), Anticoccidials (Nicarb®, Aviax®, Aviax Plus®, Coxistac®, amprolium, Avatec®, Bovatec®, Cygro®, Gromax®, Deccox®/Avi-Deccox®, Robenz®/Cycostat®, Zoamix®), Anthelmintics (Bloat Guard®, Banminth®, Rumatel®, Cerdimix®). Also processing aids for ethanol fermentation.
- Nutritional specialties: OmniGen® family, Animate®, Magni-Phi®, MicroLife®Prime, Cellerate Yeast Solutions®, Ephicax®, AB20®.
- Vaccines: V.H.™, Tailor-Made® Vaccines, MVP adjuvants® (Emulsigen®, Carbigen®, Polygen®), TAbic® M.B., MJPRRS®, TAbic® IB VAR, TAbic® IBVAR206, MB-1®, Phivax® SLE, Phi-Shield® Vaccines. New inactivated subunit Infectious Bursal Disease Virus and Egg Drop Syndrome vaccines.
- Companion Animal Products: Rejensa® joint care supplement for dogs, with a pipeline including a potential treatment for mitral valve disease in dogs, a novel pain management product, and two oral care formulations.
Market Dynamics:
- Key customer types: Livestock sector (poultry, swine, beef and dairy cattle, aquaculture) and companion animal owners.
- Geographic Distribution: International operations contributed approximately 55% of Animal Health net sales for fiscal year 2025.
Sub-segment Breakdown:
- MFAs and other: $646 million revenue (+53.4% YoY)
- Nutritional specialties: $179 million revenue (+8.5% YoY)
- Vaccines: $137 million revenue (+13.2% YoY)
Mineral Nutrition
Financial Performance:
- Revenue: $253 million (+3.7% YoY)
- Operating Margin: Adjusted EBITDA was $21 million (8.3% of segment revenue)
- Key Growth Drivers: Modest revenue growth in fiscal year 2025.
Product Portfolio:
- Manufactures and markets approximately 380 formulations of trace minerals, including zinc, manganese, copper, and iron.
- Products include GemStone (chelated organic trace minerals) and Vistore portfolio (chloride mineral option).
Market Dynamics:
- Competitive positioning within segment: Primarily serves North America.
- Key customer types and market trends: Livestock sector.
Performance Products
Financial Performance:
- Revenue: $80 million (+17.6% YoY)
- Operating Margin: Adjusted EBITDA was $11 million (13.8% of segment revenue)
- Key Growth Drivers: Revenue growth in fiscal year 2025.
Product Portfolio:
- Manufactures specialty ingredients for personal care, industrial chemical, and chemical catalyst industries.
Market Dynamics:
- Competitive positioning within segment: Primarily operates in the United States through PhibroChem, Ferro Metal and Chemical Corporation Limited, and Phibro-Tech, Inc.
Capital Allocation Strategy
Shareholder Returns:
- Dividend Payments: $19.4 million in fiscal year 2025.
- Future Capital Return Commitments: The Board declared a cash dividend of $0.12 per share on July 29, 2025, payable September 24, 2025. The 2024 Credit Facilities permit distributions subject to annual limitations and a quarterly maximum Net Leverage Ratio of 4.0x.
Balance Sheet Position:
- Cash and Equivalents: $68.0 million
- Total Debt: $718.7 million (including current portion)
- Net Cash Position: -$650.6 million (Net Debt)
- Debt Maturity Profile: Aggregate maturities of long-term debt under the 2024 Credit Agreement total $725.1 million, with $16.3 million due in 2026. Total estimated interest payments are $215.2 million. As of June 30, 2025, $87.0 million was outstanding under the 2024 Revolver, with $2.5 million in outstanding letters of credit, leaving $220.5 million available.
Cash Flow Generation:
- Operating Cash Flow: $80.1 million
- Free Cash Flow: $41.8 million (Operating Cash Flow less Capital Expenditures)
- Cash Conversion Metrics: Working capital increased to $456.3 million in 2025 from $312.0 million in 2024, with a current ratio of 2.65:1.
Operational Excellence
Production & Service Model: Phibro Animal Health Corporation manufactures its products across a global network of facilities. The company focuses on fermentation development, micro-biological strain improvement, vaccine development, chemical synthesis and formulation, nutritional specialty product development, and ethanol-related products. Its service model includes a sales, marketing, and technical support organization of over 520 employees.
Facility Network:
- Manufacturing: Buenos Aires, Argentina; Braganca Paulista, Brazil; Guarulhos, Brazil; Heliópolis, Brazil; Sligo, Ireland; Beit Shemesh, Israel; Neot Hovav, Israel; Petach Tikva, Israel; Sarasota, Florida; Chillicothe, Illinois; Mendon, Illinois; St. Paul, Minnesota; Omaha, Nebraska; State College, Pennsylvania; Salisbury, Maryland; Willow Island, West Virginia; Chicago Heights, Illinois; Eagle Grove, Iowa; Suzhou, China; Medolla, Italy; Quincy, Illinois.
- Research & Development: R&D efforts focus on fermentation development, micro-biological strain improvement, vaccine development, chemical synthesis and formulation, nutritional specialty product development, and ethanol-related products.
- Distribution: Independence, Missouri (warehousing). The company utilizes approximately 370 distributors globally.
Operational Metrics: The average worldwide collection period for accounts receivable is approximately 60 days.
Market Access & Customer Relationships
Go-to-Market Strategy: Distribution Channels:
- Direct Sales: Supported by a sales, marketing, and technical support organization of over 520 employees.
- Channel Partners: Utilizes approximately 370 distributors.
Customer Portfolio: Enterprise Customers:
- Tier 1 Clients: Serves approximately 4,500 customers globally.
Geographic Revenue Distribution:
- United States: 57.1% of total revenue
- Latin America and Canada: 23.1% of total revenue
- Europe, Middle East and Africa: 12.3% of total revenue
- Asia Pacific: 7.5% of total revenue
- Growth Markets: International operations contributed approximately 55% of Animal Health net sales for fiscal year 2025, indicating a strong focus on global expansion.
Competitive Intelligence
Market Structure & Dynamics
Industry Characteristics: The company operates in the animal health and mineral nutrition markets, serving the livestock sector (poultry, swine, beef and dairy cattle, aquaculture) and expanding into companion animal products. The market is influenced by factors such as animal disease outbreaks and regulatory restrictions on antibacterials.
Competitive Positioning Matrix:
| Competitive Factor | Company Position | Key Differentiators |
|---|---|---|
| Technology Leadership | Moderate | Focus on fermentation development, micro-biological strain improvement, vaccine development, and nutritional specialty products. |
| Market Share | Competitive | Believes its medicated feed additive sales were the third largest in the animal health market following the Zoetis Inc. acquisition. |
| Cost Position | Not disclosed | Not explicitly mentioned. |
| Customer Relationships | Strong | Serves approximately 4,500 customers in about 90 countries with a dedicated sales, marketing, and technical support organization. |
Direct Competitors
Primary Competitors:
- Boehringer Ingelheim International GmbH: Competitive overlap in animal health.
- Ceva Santé Animale: Competitive overlap in animal health.
- Elanco Animal Health Incorporated: Competitive overlap in animal health.
- Huvepharma Inc.: Competitive overlap in animal health.
- Merck & Co., Inc. (Merck Animal Health and MSD Animal Health): Competitive overlap in animal health.
- Southeastern Minerals, Inc.: Competitive overlap in mineral nutrition.
- Zoetis Inc.: Competitive overlap in animal health, though Phibro Animal Health Corporation recently acquired a significant portfolio from them.
Competitive Response Strategy: Phibro Animal Health Corporation's strategy includes strategic acquisitions (e.g., Zoetis Inc. MFA portfolio), expansion of vaccine manufacturing capabilities, and investment in a companion animal product pipeline to diversify and strengthen its market position.
Risk Assessment Framework
Strategic & Market Risks
Market Dynamics:
- Animal Disease Outbreaks: Risks from outbreaks of animal diseases such as African Swine Fever and H5N1 avian influenza, which can impact demand for products.
- Perceived Adverse Effects: Risks related to perceived adverse effects on human health from products, potentially impacting product acceptance and sales.
Financial & Regulatory Risks
Market & Financial Risks:
- Credit & Liquidity: Increased long-term debt to $615.4 million in 2025 from $282.3 million in 2024, primarily due to the Zoetis Inc. acquisition, increasing interest expense. The 2024 Credit Facilities include a quarterly maximum Net Leverage Ratio of 4.0x.
Regulatory & Compliance Risks:
- Industry Regulation: Restrictions on antibacterials (e.g., FDA Guidance 273) and potential FDA withdrawal of products like Mecadox (carbadox) pose regulatory risks.
Innovation & Technology Leadership
Research & Development Focus: Core Technology Areas:
- Fermentation Development: Investment in improving fermentation processes.
- Micro-biological Strain Improvement: Focus on enhancing microbial strains.
- Vaccine Development: Development of new vaccines, including inactivated subunit Infectious Bursal Disease Virus and Egg Drop Syndrome vaccines, and expansion into autogenous vaccines for swine, poultry, and aquaculture.
- Chemical Synthesis and Formulation: Development in chemical product creation.
- Nutritional Specialty Product Development: Innovation in nutritional supplements.
- Ethanol-related Products: Development of processing aids for ethanol fermentation.
- Companion Animal Products: Development of products for dogs, including joint care, mitral valve disease treatment, pain management, and oral care.
Tax Strategy & Considerations
Tax Profile:
- Effective Tax Rate: 29.0% (2025), 77.9% (2024), 39.7% (2023).
Insurance & Risk Transfer
Risk Management Framework:
- Insurance Coverage: Financial assurance of $15.2 million was provided via surety bonds or letters of credit as of June 30, 2025, for environmental liabilities.